Takeda has expanded its capabilities in the oncology field with the purchase of small molecule drugs specialist Intellikine
Via its subsidiary Takeda American Holdings, the company will acquire Intellikine for an initial cost of $190 million (120.47 million pounds), with an additional $120 million dependent on clinical development milestones.
Intellikine’s portfolio includes numerous promising small molecule kinase inhibitors that function by selectively targeting isoforms of the phosphoinositide-3 kinase/mammalian target of rapamycin pathway.
These include the cancer cell inhibitor therapies INK128 and INK111, both of which will now be added to Takeda’s product pipeline, with its global oncology division Millennium set to handle development.
Dr Deborah Dunsire, president and chief executive officer of Millennium, said: “As single agents or in different combinations with novel molecules within our robust pipeline, we anticipate that these assets will be able to deliver transforming therapies to cancer patients.”
Earlier this month, Takeda and Millennium published new clinical study data highlighting the benefits of Velcade, their treatment for multiple myeloma.
Tags: myeloma, small molecule, Takeda Source
This post is in: News